Sana Biotechnology Inc. (SANA) continues to draw attention for its progress across multiple cell therapy programs, with recent regulatory and clinical developments positioning the company for key milestones over the next 12 to 18 months.
Shares recently traded around $3.39, reflecting a strong recovery from earlier lows, though still below the 52-week high of $7.30.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com